EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma	EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma	osimertinib + gefitinib Resistant: C4 – Case Studies osimertinib + gefitinib Resistant : C4	osimertinib + gefitinib Resistant: C4 – Case Studies osimertinib + gefitinib Resistant : C4
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma	EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma	icotinib Resistant: C4 – Case Studies icotinib Resistant : C4	icotinib Resistant: C4 – Case Studies icotinib Resistant : C4
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma	EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma	bevacizumab + osimertinib Resistant: C4 – Case Studies bevacizumab + osimertinib Resistant : C4	bevacizumab + osimertinib Resistant: C4 – Case Studies bevacizumab + osimertinib Resistant : C4
EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma	EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation	Lung Adenocarcinoma	bevacizumab + icotinib Resistant: C4 – Case Studies bevacizumab + icotinib Resistant : C4	bevacizumab + icotinib Resistant: C4 – Case Studies bevacizumab + icotinib Resistant : C4

EGFR exon 19 deletion + EGFR T790M + EGFR C797S + CTNNB1 exon 3 mutation

Associations